In its ongoing patent litigation over cholesterol lowering drug atorvastatin (Lipitor) against India's Ranbaxy Laboratories, Pfizer said on Tuesday in a court in Ireland had ruled in its favour.
The world's largest drugmaker said in a statement that the high court in Dublin had ruled that the basic patent covering atorvastatin -- the active ingredient in Lipitor-- would be infringed by Ranbaxy's generic product.
"The decision, which is subject to a possible appeal, prevents Ranbaxy from launching its drug before the basic Lipitor patent expires in November 2011,"